

Press release

Change in the Board of Directors of FluoGuide

Copenhagen, Denmark, 25 January 2021 – FluoGuide A/S (“FluoGuide” or the “Company”) announces that the chairman of the Board of Directors, Arne Ferstad, will not stand for re-election at the upcoming Annual General Meeting

Arne Ferstad, the Chairman of the Board of Directors, has notified FluoGuide that he will not stand for re-election at the upcoming annual general meeting on the 9th of February, 2021, for personal reasons.

“I would like to thank Arne for his great contribution to FluoGuide since the very beginning. It has been a pleasure working together with Arne over these last years, and I wish him the very best” says Morten Albrechtsen, CEO.

The other members of the Board of Directors are Lisa Micaela Sjøkvist, Shomit Ghose, Peter Mørch Eriksen and Andreas Kjær, who are all proposed to be re-elected at the Annual General Meeting on the 9th of February 2021.

For further information, please contact:

Morten Albrechtsen, CEO

FluoGuide A/S

+45 24 25 62 66

ma@fluoguide.com

This information is information that FluoGuide A/S is obliged to publish in accordance with the EU Market Abuse Regulation. The information was provided by the contact person set out above for publication on 25 January 2021.

About FluoGuide

FluoGuide’s primary focus is to maximize surgical outcomes in oncology. The Company’s first product, FG001, is designed to improve surgical precision by illuminating cancer cells intraoperatively. The improved precision enabled by FluoGuide’s products has a dual benefit – it reduces both the frequency of local recurrence post-surgery and lessens surgical sequelae. Ultimately, the improved precision will improve a patient’s chance of achieving a complete cure and will lower system-wide healthcare costs. The Company is conducting a proof-of-concept clinical study (phase I/II) to demonstrate the effect of FG001 in patients with high grade glioma.